Earnings

HCA Healthcare Affirms FY2026 GAAP EPS Guidance of $28.70-$30.50 vs $29.70 Est; Affirms FY2026 Sales Guidance of $77.000B-$79.500B vs $78.457B Est

Jul 24, 2026 · 07:31 AM ET· updated 2h ago

HCA Healthcare (NYSE:HCA) affirms FY2026 GAAP EPS guidance from $28.70-$30.50 to $28.70-$30.50 vs $29.70 analyst estimate. Affirms FY2026 sales outlook from $77.000 billion-$79.500 billion to $77.000 billion-$79.500

Why It Matters

HCA Healthcare kept its predictions for next year's earnings and sales the same as before. When a big company sticks with what it said earlier, it usually means things are going about as planned.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

HCA392.94

+16.44 (+4.37%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.